Drugs watchdog faces legal review
The NHS drugs watchdog is to face a judicial review in court for the first time over the guidance it offers. Two firms have been granted the review over the way the National Institute for Health and Clinical Excellence reached its conclusion on Alzheimer's drugs. NICE ruled NHS patients with newly diagnosed, mild Alzheimer's disease should not be prescribed the drugs. Eisai and Pfizer said the process was unfair, but NICE said the claims were without foundation.